Case Report: No radiographic evidence of disease for 45 months in a patient with recurrent clear cell renal cell carcinoma treated with third-line combination therapy utilizing toripalimab and axitinib.

Yervoy (ipilimumab) - BMS

everolimus - Generic mfg.

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Lenvima (lenvatinib) - Eisai, Merck (MSD)

Keytruda (pembrolizumab) - Merck (MSD)

Cabometyx (cabozantinib tablet) - Exelixis

Loqtorzi (toripalimab-tpzi) - Shanghai Junshi Bioscience, Coherus Oncology

axitinib - Generic mfg.

http://www.ncbi.nlm.nih.gov/pubmed/42780674

Juan Lang; Ye Yang; Zhongkui Xiong

Sep 25, 2026